-$0.05 Earnings Per Share Expected for Sesen Bio, Inc. (NASDAQ:SESN) This Quarter

Brokerages expect Sesen Bio, Inc. (NASDAQ:SESN – Get Rating) to report earnings per share of ($0.05) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Sesen Bio’s earnings. Sesen Bio posted earnings of ($0.35) per share in the same quarter last year, which indicates a positive year over year growth rate of 85.7%. The business is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Sesen Bio will report full-year earnings of ($0.33) per share for the current year, with EPS estimates ranging from ($0.46) to ($0.19). For the next year, analysts expect that the firm will post earnings of ($0.27) per share, with EPS estimates ranging from ($0.35) to ($0.19). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that follow Sesen Bio.

Sesen Bio (NASDAQ:SESN – Get Rating) last announced its quarterly earnings data on Monday, February 28th. The company reported $0.04 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.11.

Several research analysts have commented on the stock. Zacks Investment Research upgraded shares of Sesen Bio from a “sell” rating to a “hold” rating in a report on Friday. StockNews.com initiated coverage on shares of Sesen Bio in a report on Thursday, March 31st. They issued a “hold” rating for the company.

Shares of Sesen Bio stock traded up $0.01 during trading on Monday, hitting $0.51. The stock had a trading volume of 1,986,289 shares, compared to its average volume of 2,111,481. The business has a fifty day moving average of $0.64 and a two-hundred day moving average of $0.83. Sesen Bio has a fifty-two week low of $0.50 and a fifty-two week high of $6.04.

Several hedge funds have recently bought and sold shares of SESN. Morgan Stanley boosted its holdings in shares of Sesen Bio by 3,442.5% during the second quarter. Morgan Stanley now owns 190,446 shares of the company’s stock worth $880,000 after purchasing an additional 185,070 shares during the period. Royal Bank of Canada boosted its holdings in shares of Sesen Bio by 9,763.3% during the second quarter. Royal Bank of Canada now owns 11,836 shares of the company’s stock worth $55,000 after purchasing an additional 11,716 shares during the period. Bank of America Corp DE boosted its holdings in shares of Sesen Bio by 213.1% during the second quarter. Bank of America Corp DE now owns 35,321 shares of the company’s stock worth $163,000 after purchasing an additional 24,041 shares during the period. Invesco Ltd. acquired a new stake in Sesen Bio in the second quarter valued at approximately $337,000. Finally, Parametric Portfolio Associates LLC acquired a new stake in Sesen Bio in the second quarter valued at approximately $388,000. Institutional investors and hedge funds own 24.79% of the company’s stock.

About Sesen Bio (Get Rating)

Sesen Bio, Inc, a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. Its lead product candidates include Vicineum, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer; to treat non-muscle invasive carcinoma in situ of the bladder in patients previously treated with BCG; and for the treatment of squamous cell carcinoma of the head and neck, as well as VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule-positive solid tumors.

Featured Articles